What Physicians Need to Know Before a Private Equity Firm Buys Their Practice

Private equity rolled up over 1,400 physician practices last year. If you're a partner in a practice that's fielded calls from PE-backed platforms - or if you're already in deal discussions - the financial decisions you make in the coming 6 to 18 months will determine more about your retirement timeline than almost anything else to this point in your career.

I've worked with physicians on both sides of these transactions: those who planned well and those who learned expensive lessons. Here's what actually matters.

Why is private equity so interested in physician practices right now?

PE firms see fragmented, cash-flowing businesses with consolidation upside. They buy practices at one EBITDA multiple, combine them into a larger platform, and exit at a higher multiple - often within 5 to 7 years. Your practice is the raw material.

The typical structure involves you selling a stake for cash and rolling the remaining equity into the new platform. That rollout equity is where the second bite of the apple supposedly comes from. Whether that second bite materializes depends heavily on deal terms you negotiate now, not later.

What does the typical deal structure actually look like?

Most transactions split into two components: cash at close and rollover equity. You might sell 70% of your ownership for cash and retain 30% as equity in the new hold company

The cash portion often gets taxed as a mix of ordinary income and capital gains depending on how your practice entity is structured - S-corp vs. C-corp vs. partnership - and how the deal is characterized. Asset sales versus stock sales carry different tax consequences. The rollover "new" equity isn't taxed at close because it's treated as a continuation of your investment, but the terms governing that equity matter enormously. Liquidation preferences, anti-dilution provisions, and governance rights can make a 30% stake worth far less than 30% of eventual proceeds.

How should I think about the tax treatment of the cash portion?

The single biggest variable is whether the buyer structures this as an asset purchase or a stock purchase - and within an asset purchase, how the purchase price gets allocated.

In an asset sale, proceeds allocated to goodwill and equipment generally receive capital gains treatment. But amounts allocated to covenants not to compete, consulting agreements, or employment arrangements get taxed as ordinary income - currently up to 37% federal plus state, versus 20% for long-term capital gains plus the 3.8% net investment income tax.

Buyers prefer asset purchases for the step-up in basis. Sellers often prefer stock sales for cleaner capital gains treatment. There's usually room to negotiate, but you need tax counsel and a financial advisor modeling scenarios before you sign a letter of intent - not after.

What makes rollover equity risky - or valuable?

The pitch is simple: roll over equity, the platform grows, and your 30% stake becomes worth more than your original 100% ownership. Sometimes that happens. Often it doesn't.

Three things to scrutinize. First, liquidation preferences: if the PE fund holds preferred equity with a 1x or 2x preference, they get paid first in any exit. Your common rollover equity might get nothing in a flat or modest outcome. Second, the timeline and exit path: PE funds have finite lives, usually 5 to 7 years for the investment period. If the platform underperforms or markets turn, the exit might happen at an inopportune time. Third, governance: you likely won't have meaningful control over when to sell, to whom, or at what price.

Rollover equity is not the same as owning your practice. It's a minority stake in a leveraged holding company controlled by a financial sponsor with different incentives than yours.

What needs to happen before I sign a letter of intent?

The LOI feels non-binding - and most provisions are - but it sets deal momentum. Once signed, you're negotiating against yourself to change major terms.

Before that signature, you need: a clear understanding of the proposed structure and your tax exposure under different allocation scenarios; an independent valuation opinion if you have any doubt about whether the multiple is fair; employment agreement terms in at least preliminary form - salary, bonus structure, call schedule, non-compete scope and duration; and a financial plan stress-testing what your life looks like if the rollover equity ends up worth zero.

I tell physicians: think of the rollover equity as a lottery ticket with decent odds. If you can't retire comfortably on just the cash at close, reconsider the deal or negotiate for more cash and less rollover.

How do employment terms after close affect the economics?

Most deals require you to stay employed for 3 to 5 years, sometimes longer. Your compensation during that period isn't a side issue - it's a major economic term.

If your post-close salary plus bonus drops $150,000 annually from what you were earning as an owner, that's $750,000 over five years. Factor that into the headline valuation. Similarly, if your call burden increases or administrative autonomy disappears, there's a quality-of-life cost that doesn't show up on the term sheet.

Non-compete provisions also matter. A 2-year, 50-mile non-compete in a metro area might be manageable. The same terms in a smaller market could functionally end your career if things go sideways.

Should I accelerate retirement contributions before the sale?

Yes - and the window may be shorter than you think. If your practice sponsors a cash balance plan, the contribution limits can shelter $300,000 or more annually, depending on your age. Contributions reduce practice earnings, which reduces the EBITDA the buyer is paying a multiple on.

There's a tension here. Every dollar you contribute pre-sale is a dollar that doesn't flow through the valuation. But it's also a dollar you keep tax-deferred rather than splitting with the buyer. For physicians within 5 to 10 years of retirement, maximizing cash balance contributions before a sale often makes sense mathematically - you're trading maybe 4 to 6x EBITDA on that dollar for keeping 100% of it in a tax-advantaged account.

The timing requires planning with your CPA and the plan actuary, ideally 12 to 24 months before a deal closes.

What do generalist financial advisors typically miss in these transactions?

Three things, consistently. First, they focus on the headline multiple without modeling the after-tax, after-allocation, after-employment-adjustment reality. A 10x EBITDA deal can net very differently depending on structure.

Second, they underestimate the complexity of integrating a lump-sum liquidity event into a retirement plan that was previously built around W-2 income and annual contributions. The investment policy, tax location, withdrawal sequencing - it all changes.

Third, they don't push back on rollover equity terms because they don't understand what they're looking at. Preferred equity structures, participation rights, tag-along provisions - these aren't exotic concepts in PE deals, but they're unfamiliar territory for advisors whose clients are mostly accumulating 401(k) balances.

What's the single most important question to ask myself before proceeding?

Can I retire comfortably if the rollover equity goes to zero and my employment ends the day after close?

If the answer is yes, you have negotiating leverage and optionality. If the answer is no, you're more dependent on the deal than you should be - which means either negotiating harder on terms or waiting until your financial position is stronger.

These transactions can be genuinely wealth-creating. But they can also convert a stable, high-income practice into an illiquid minority stake in a levered platform you don't control. The difference between those outcomes is almost entirely determined by decisions made before closing, not after.

If you're a physician partner evaluating a PE transaction - or expecting to in the next few years - I'm happy to talk through the planning framework in a 30-minute discovery call.